107 related articles for article (PubMed ID: 7353778)
1. [Prolactin in serum and anamnestic data of women with cystic disease of the breast (author's transl)].
Bischoff J; Rebhan EM; Prestele H; Becker H
Geburtshilfe Frauenheilkd; 1980 Jan; 40(1):65-71. PubMed ID: 7353778
[TBL] [Abstract][Full Text] [Related]
2. Circadian variation of serum prolactin and TSH of women in health or with mammary carcinoma, fibroadenoma or fibrocystic mastopathy.
Tarquini B; Gheri R; Romano S; Costa A; Cagnoni M; Lee JK; Halberg F
Int J Chronobiol; 1980; 7(2):101-15. PubMed ID: 7450919
[TBL] [Abstract][Full Text] [Related]
3. Effect of a low-fat diet on hormone levels in women with cystic breast disease. II. Serum radioimmunoassayable prolactin and growth hormone and bioactive lactogenic hormones.
Rose DP; Cohen LA; Berke B; Boyar AP
J Natl Cancer Inst; 1987 Apr; 78(4):627-31. PubMed ID: 3470539
[TBL] [Abstract][Full Text] [Related]
4. Serum prolactin levels in patients with fibrocystic breast disease.
Peters F; Schuth W; Scheurich B; Breckwoldt M
Obstet Gynecol; 1984 Sep; 64(3):381-5. PubMed ID: 6431348
[TBL] [Abstract][Full Text] [Related]
5. Mammary cancer risk: circulating TSH and prolactin, fibrocystic breast disease in chronoepidemiologic perspective.
Tarquini B; Benvenuti M; Legnaioli M; Bazzani M; Cagnoni M; Halberg F
Cancer Detect Prev; 1981; 4(1-4):525-34. PubMed ID: 7349819
[TBL] [Abstract][Full Text] [Related]
6. Serum androgen levels and the menstrual cycle in women with benign or malignant breast disease.
England PC; Sellwood RA; Knyba RE; Irvine JD
Clin Oncol; 1981 Sep; 7(3):213-9. PubMed ID: 6211319
[No Abstract] [Full Text] [Related]
7. Serum prolactin and oestradiol levels in women with cyclical mastalgia.
Watt-Boolsen S; Andersen AN; Blichert-Toft M
Horm Metab Res; 1981 Dec; 13(12):700-2. PubMed ID: 7319468
[TBL] [Abstract][Full Text] [Related]
8. Treatment of fibrocystic disease of the breast with a prolactin inhibitor: 2-Br-alpha-ergocryptine (CB-154).
Martin-Comin J; Pujol-Amat P; Cararach V; Davi E; Robyn C
Obstet Gynecol; 1976 Dec; 48(6):703-6. PubMed ID: 1036613
[TBL] [Abstract][Full Text] [Related]
9. Effect of a low-fat diet on hormone levels in women with cystic breast disease. I. Serum steroids and gonadotropins.
Rose DP; Boyar AP; Cohen C; Strong LE
J Natl Cancer Inst; 1987 Apr; 78(4):623-6. PubMed ID: 3104646
[TBL] [Abstract][Full Text] [Related]
10. [Mastopathy and breast cancer: is there a typical hormone profile?].
Völker W; Leipert KP; Gehrlings H; Stauch G; von zur Mühlen A; Schneider J
Geburtshilfe Frauenheilkd; 1986 May; 46(5):284-9. PubMed ID: 3087811
[TBL] [Abstract][Full Text] [Related]
11. [Plasma-prolactin concentrations in breast cancer at various stages, in mastopathy and other malignant tumors].
Holtkamp W; von Heyden D; Rauschecker H; Nagel GA
Schweiz Med Wochenschr; 1983 Oct; 113(41):1513-20. PubMed ID: 6635641
[TBL] [Abstract][Full Text] [Related]
12. [Interaction between beta-endorphin, steroids and peptide hormones in fibrocystic lesions of the female breast].
Schurz B
Wien Klin Wochenschr Suppl; 1991; 187():3-26. PubMed ID: 1648846
[TBL] [Abstract][Full Text] [Related]
13. [Serum prolactin level in patients with mastopathy. Clinical significance].
Peters F; Breckwoldt M
Verh Dtsch Ges Pathol; 1985; 69():401-4. PubMed ID: 3938116
[No Abstract] [Full Text] [Related]
14. Cystic disease, family history of breast cancer, and use of oral contraceptives.
Vakil DV; Elinson L; Morgan RW
Cancer Detect Prev; 1981; 4(1-4):511-5. PubMed ID: 7349817
[TBL] [Abstract][Full Text] [Related]
15. Beta-endorphin, steroids, and prolactin. Immunoassay in breast cysts and blood.
Schön HJ; Schurz B; Wenzl R; Knogler W; Kubista E
Arch Pathol Lab Med; 1993 Mar; 117(3):248-53. PubMed ID: 8442670
[TBL] [Abstract][Full Text] [Related]
16. Oral contraception and breast pathology.
Ragni N; Boccardo E; Viglino S; Larosa E
Acta Eur Fertil; 1981 Jun; 12(2):141-63. PubMed ID: 6794288
[TBL] [Abstract][Full Text] [Related]
17. [Plasma levels of prolactin in women with dysplasia and tumors of the breast (fibroadenoma and carcinoma of the breast)].
Iturburu Belmonte IM; Basáñez Amuchastegui A; Jiménez Jiménez E; López de Tejada Cabeza I; Goicoechea García J; Méndez Martín J
Rev Quir Esp; 1988; 15(1):17-21. PubMed ID: 3153353
[No Abstract] [Full Text] [Related]
18. Treatment of benign fibrocystic disease of the breast with 2-bromo-alpha-ergocryptine (CB 154).
Santoro C; Cappa M; Moretti C; Fabbri A; La Vecchia V; Romano Marcellino L; Fraioli F
Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):479-81. PubMed ID: 6815107
[TBL] [Abstract][Full Text] [Related]
19. [Antiprolactin therapy in the treatment of benign lesions of the breast. Comparison of bromocryptine and methergoline].
Mussa A; Sandrucci S; Dogliotti L
Minerva Med; 1979 Nov; 70(51):3493-8. PubMed ID: 522987
[TBL] [Abstract][Full Text] [Related]
20. Prolactin and breast cancer risk.
Ingram DM; Nottage EM; Roberts AN
Med J Aust; 1990 Oct; 153(8):469-73. PubMed ID: 2215338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
